Clover Health Investments, Corp. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2024. The company experienced a notable increase in total revenues, which reached $330.986 million, up from $306.028 million in the same quarter of 2023, marking an 8.2% increase. For the nine months ended September 30, 2024, total revenues were $1.034 billion, compared to $948.158 million for the same period in 2023, reflecting a 9.1% increase. This growth was primarily driven by a rise in premiums earned, net, which increased to $322.579 million in Q3 2024 from $301.230 million in Q3 2023.
Despite the revenue growth, Clover Health reported a net loss of $9.155 million for Q3 2024, a significant improvement from the $41.469 million loss in Q3 2023. The loss from continuing operations also improved to $(8.785) million from $(33.616) million year-over-year. For the nine months ended September 30, 2024, the net loss was $(20.917) million, compared to $(142.889) million for the same period in 2023, indicating an 85.4% improvement.
The company’s total assets increased to $653.013 million as of September 30, 2024, up from $570.671 million at the end of 2023. Cash and cash equivalents saw a substantial rise, reaching $287.956 million compared to $116.407 million at the end of 2023. However, total liabilities also increased to $310.847 million from $284.277 million, with unpaid claims rising to $166.070 million from $135.737 million.
Strategically, Clover Health exited the ACO REACH Model effective December 1, 2023, following a reduction in participating physicians. This decision was part of a broader restructuring initiative that included a workforce reduction of approximately 10% to align costs with revenue. The company launched Counterpart Health, Inc. in Q2 2024, aimed at extending its technology to Medicare Advantage payors and providers.
Clover Health's stock-based compensation decreased to $28 million for Q3 2024 from $33.1 million in Q3 2023, and for the nine months, it fell to $84.7 million from $107.8 million. The company also reported a decrease in general and administrative expenses, which dropped by 14% to $35.2 million in Q3 2024.
Overall, Clover Health's financial performance reflects a strategic shift towards enhancing operational efficiency and revenue growth, despite ongoing challenges in the insurance market.
About CLOVER HEALTH INVESTMENTS, CORP. /DE
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.